Feasibility of 99m Tc-MIP-1404 for SPECT/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer: a case series of 9 patients

Standard

Feasibility of 99m Tc-MIP-1404 for SPECT/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer: a case series of 9 patients. / Köhler, Daniel; Sauer, Markus; Klutmann, Susanne; Apostolova, Ivayla; Lehnert, Wencke; Budäus, Lars; Knipper, Sophie; Maurer, Tobias.

in: J NUCL MED, Jahrgang 64, Nr. 1, 01.2023, S. 59-62.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungKurzpublikationForschungBegutachtung

Harvard

APA

Vancouver

Bibtex

@article{7829fa17a6cd4780a8c9d3aaa5edf818,
title = "Feasibility of 99m Tc-MIP-1404 for SPECT/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer: a case series of 9 patients",
abstract = "This case series evaluated the feasibility of prostate-specific membrane antigen (PSMA) radioguided surgery (RGS) with 99mTc-MIP-1404 in recurrent prostate cancer. Methods: 9 patients with PSMA-positive lesions on PET/CT received 99mTc-MIP-1404 (median 747 MBq, interquartile range (IQR) 710 - 764) 17.2 hours (IQR 16.9 - 17.5) before SPECT/CT and 22.3 hours (IQR 20.8 - 24.0) before RGS. Results: 17 PSMA-positive lesions were detected on PET/CT (median short axis diameter 4 mm, IQR 3 - 6; median SUVmax 8.9, IQR 5.2 - 12.6). 9/17 (52.9%) were visible on SPECT/CT (median SUVmax 13.8, IQR 8.0 - 17.9). Except for 2 foci, all PET/CT-positive findings demonstrated intraoperative count rates above the background (median counts 31, IQR 17 - 89) and were lymph node metastases. Moreover, PSMA-RGS identified 2 additional metastases compared to PET/CT. Prostate-specific antigen values decreased after RGS in 6/9 (67%) patients. Conclusion: PSMA-RGS with 99mTc-MIP-1404 identified lymph node metastases in all patients including two additional lesions compared to PET/CT. ",
keywords = "Male, Humans, Positron Emission Tomography Computed Tomography/methods, Lymphatic Metastasis, Feasibility Studies, Neoplasm Recurrence, Local/diagnostic imaging, Prostatic Neoplasms/diagnostic imaging, Single Photon Emission Computed Tomography Computed Tomography, Surgery, Computer-Assisted/methods, Gallium Radioisotopes",
author = "Daniel K{\"o}hler and Markus Sauer and Susanne Klutmann and Ivayla Apostolova and Wencke Lehnert and Lars Bud{\"a}us and Sophie Knipper and Tobias Maurer",
note = "{\textcopyright} 2023 by the Society of Nuclear Medicine and Molecular Imaging.",
year = "2023",
month = jan,
doi = "10.2967/jnumed.122.263892",
language = "English",
volume = "64",
pages = "59--62",
journal = "J NUCL MED",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "1",

}

RIS

TY - JOUR

T1 - Feasibility of 99m Tc-MIP-1404 for SPECT/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer: a case series of 9 patients

AU - Köhler, Daniel

AU - Sauer, Markus

AU - Klutmann, Susanne

AU - Apostolova, Ivayla

AU - Lehnert, Wencke

AU - Budäus, Lars

AU - Knipper, Sophie

AU - Maurer, Tobias

N1 - © 2023 by the Society of Nuclear Medicine and Molecular Imaging.

PY - 2023/1

Y1 - 2023/1

N2 - This case series evaluated the feasibility of prostate-specific membrane antigen (PSMA) radioguided surgery (RGS) with 99mTc-MIP-1404 in recurrent prostate cancer. Methods: 9 patients with PSMA-positive lesions on PET/CT received 99mTc-MIP-1404 (median 747 MBq, interquartile range (IQR) 710 - 764) 17.2 hours (IQR 16.9 - 17.5) before SPECT/CT and 22.3 hours (IQR 20.8 - 24.0) before RGS. Results: 17 PSMA-positive lesions were detected on PET/CT (median short axis diameter 4 mm, IQR 3 - 6; median SUVmax 8.9, IQR 5.2 - 12.6). 9/17 (52.9%) were visible on SPECT/CT (median SUVmax 13.8, IQR 8.0 - 17.9). Except for 2 foci, all PET/CT-positive findings demonstrated intraoperative count rates above the background (median counts 31, IQR 17 - 89) and were lymph node metastases. Moreover, PSMA-RGS identified 2 additional metastases compared to PET/CT. Prostate-specific antigen values decreased after RGS in 6/9 (67%) patients. Conclusion: PSMA-RGS with 99mTc-MIP-1404 identified lymph node metastases in all patients including two additional lesions compared to PET/CT.

AB - This case series evaluated the feasibility of prostate-specific membrane antigen (PSMA) radioguided surgery (RGS) with 99mTc-MIP-1404 in recurrent prostate cancer. Methods: 9 patients with PSMA-positive lesions on PET/CT received 99mTc-MIP-1404 (median 747 MBq, interquartile range (IQR) 710 - 764) 17.2 hours (IQR 16.9 - 17.5) before SPECT/CT and 22.3 hours (IQR 20.8 - 24.0) before RGS. Results: 17 PSMA-positive lesions were detected on PET/CT (median short axis diameter 4 mm, IQR 3 - 6; median SUVmax 8.9, IQR 5.2 - 12.6). 9/17 (52.9%) were visible on SPECT/CT (median SUVmax 13.8, IQR 8.0 - 17.9). Except for 2 foci, all PET/CT-positive findings demonstrated intraoperative count rates above the background (median counts 31, IQR 17 - 89) and were lymph node metastases. Moreover, PSMA-RGS identified 2 additional metastases compared to PET/CT. Prostate-specific antigen values decreased after RGS in 6/9 (67%) patients. Conclusion: PSMA-RGS with 99mTc-MIP-1404 identified lymph node metastases in all patients including two additional lesions compared to PET/CT.

KW - Male

KW - Humans

KW - Positron Emission Tomography Computed Tomography/methods

KW - Lymphatic Metastasis

KW - Feasibility Studies

KW - Neoplasm Recurrence, Local/diagnostic imaging

KW - Prostatic Neoplasms/diagnostic imaging

KW - Single Photon Emission Computed Tomography Computed Tomography

KW - Surgery, Computer-Assisted/methods

KW - Gallium Radioisotopes

U2 - 10.2967/jnumed.122.263892

DO - 10.2967/jnumed.122.263892

M3 - Short publication

C2 - 35835582

VL - 64

SP - 59

EP - 62

JO - J NUCL MED

JF - J NUCL MED

SN - 0161-5505

IS - 1

ER -